Therefore, the targeting of STING signaling is now considered an essential therapeutic strategy that can convert poorly immunogenic tumors to highly immunogenic tumors, which can respond favorably to cancer immunotherapy [3,31,34]. The gene discussed is STING1; the disease is cancer.